Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues

被引:83
作者
Hubálek, F
Binda, C
Li, M
Herzig, Y
Sterling, J
Youdim, MBH
Mattevi, A
Edmondson, DE
机构
[1] Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy
[2] Emory Univ, Dept Biochem, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Chem, Atlanta, GA 30322 USA
[4] Teva Pharmaceut Ind, Div Res & Dev, IL-42504 Netanya, Israel
[5] Technion Israel Inst Technol, Fac Med, Eve Topf Ctr, IL-31096 Haifa, Israel
[6] Technion Israel Inst Technol, Fac Med, NPF Ctr, IL-31096 Haifa, Israel
[7] Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel
关键词
D O I
10.1021/jm0310885
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The inactivation of purified human recombinant monoamine oxidases (MAO) A and B by rasagiline [N-propargyl-1(R)-aminoindan] and four of its analogues [N-propargyl-1(S)-aminoindan (S-PAI), 6-hydroxy-N-propargyl-1(R)-aminoindan (R-HPAI), N-methyl-N-propargyl-1(R)-aminoindan (R-MPAI), and 6-(N-methyl-N-ethyl carbamoyloxy)-N-propargyl-1(R)-aminoindan (R-CPAI)] has been investigated. All compounds tested, with the exception of R-CPAI, form stoichiometric N(5) flavocyanine adducts with the FAD moiety of either enzyme. No H2O2 is produced during either MAO A or MAO B inactivation, which demonstrates that covalent addition occurs in a single turnover. Rasagiline has the highest specificity for MAO B, as demonstrated by a 100-fold higher inhibition potency (k(inact)/K-i) compared to MAO A, with the remaining compounds exhibiting lower isozyme specificities. MAO B and MAO A are more selective for the R-enantiomer (rasagiline) compared to the S-enantiomer (S-PAI) by 2500-fold and 17-fold, respectively. Differences in UV/vis and CD spectral data of the complexes of the studied compounds with both MAO A and MAO B are interpreted in light of crystallographic data of complexes of MAO B with rasagiline and its analogues.
引用
收藏
页码:1760 / 1766
页数:7
相关论文
共 25 条
[11]   SELECTIVE ACETYLENIC SUICIDE AND REVERSIBLE INHIBITORS OF MONOAMINE-OXIDASE TYPE-A AND TYPE-B [J].
KALIR, A ;
SABBAGH, A ;
YOUDIM, MBH .
BRITISH JOURNAL OF PHARMACOLOGY, 1981, 73 (01) :55-64
[12]   High-level expression of human liver monoamine oxidase a in Pichia pastoris:: Comparison with the enzyme expressed in Saccharomyces cerevisiae [J].
Li, M ;
Hubálek, F ;
Newton-Vinson, P ;
Edmondson, DE .
PROTEIN EXPRESSION AND PURIFICATION, 2002, 24 (01) :152-162
[13]   Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor [J].
Maruyama, W ;
Weinstock, M ;
Youdim, MBH ;
Nagai, M ;
Naoi, M .
NEUROSCIENCE LETTERS, 2003, 341 (03) :233-236
[14]   STRUCTURE OF COVALENT ADDUCT FORMED BY INTERACTION OF 3-DIMETHYLAMINO-1-PROPYNE AND FLAVINE OF MITOCHONDRIAL AMINE OXIDASE [J].
MAYCOCK, AL ;
ABELES, RH ;
SALACH, JI ;
SINGER, TP .
BIOCHEMISTRY, 1976, 15 (01) :114-125
[15]   Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A [J].
Nandigama, RK ;
Miller, JR ;
Edmondson, DE .
BIOCHEMISTRY, 2001, 40 (49) :14839-14846
[16]   High-level expression of human liver monoamine oxidase B in Pichia pastoris [J].
Newton-Vinson, P ;
Hubalek, F ;
Edmondson, DE .
PROTEIN EXPRESSION AND PURIFICATION, 2000, 20 (02) :334-345
[17]  
PARE CMB, 1976, PHARMAKOPSYCH NEURO, V9, P187
[18]   Monoamine oxidase: From genes to behavior [J].
Shih, JC ;
Chen, K ;
Ridd, MJ .
ANNUAL REVIEW OF NEUROSCIENCE, 1999, 22 :197-217
[19]  
SHOULSON I, 1989, NEW ENGL J MED, V321, P1364
[20]  
SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240